Madrigal Pharmaceuticals
MDGL
80 hedge funds and large institutions have $212M invested in Madrigal Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 17 reducing their positions, and 12 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 17
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
4% more funds holding
Funds holding: 77 → 80 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less capital invested
Capital invested by funds: $266M → $212M (-$53.6M)
42% less call options, than puts
Call options by funds: $1.88M | Put options by funds: $3.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$3.33M |
| 2 |
State Street
Boston,
Massachusetts
|
+$930K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$888K |
| 4 |
IIM
Ironwood Investment Management
Boston,
Massachusetts
|
+$681K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$670K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$9.22M |
| 2 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$1.79M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.26M |
| 4 |
Renaissance Technologies
New York
|
-$1.12M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$925K |
MDGL Hedge Fund Activity: Q1 2014 in Review
80 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2014, worth a combined $212M — down 20% from $266M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new MDGL positions and 12 closed out — a net gain of 4 holders — while 33 added to existing stakes and 17 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $3.33M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $9.22M sold.
- 80 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2014, up from 77 in Q4 2013.
- Funds reported $212M of Madrigal Pharmaceuticals stock for Q1 2014, down 20% quarter-over-quarter.
- 16 funds opened new Madrigal Pharmaceuticals positions in Q1 2014 and 12 closed out, a net change of +4 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2014 was Goldman Sachs, an estimated $3.33M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2014 was JP Morgan Chase, an estimated $9.22M sold.
Based on aggregated 13F filings for Q1 2014.